# A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

> **NCT00806923** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1044 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** Placebo
- **DRUG:** bevacizumab [Avastin]
- **DRUG:** bevacizumab [Avastin]

## Key facts

- **NCT ID:** NCT00806923
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 1044 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00806923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00806923, "A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00806923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*